Combining drugs and biologics to treat nasopharyngeal cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

1. Biocompatibility and potential anticancer activity of gadolinium oxide (GdBMC biotechnology · 2024
   Article
2. Curcumin loaded sub-30 nm targeting therapeutic lipid nanoparticles for synergistically blocking nasopharyngeal cancer growth and metastasis.Journal of nanobiotechnology · 2021
   Article
3. Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.Experimental & molecular medicine · 2015
   Review
4. Gene-modified cells for stem cell transplantation and cancer therapy.Human gene therapy · 2014
   Review

Corrections and comments

• Comment on
  Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.2014

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as